BioXcel Therapeutics (NASDAQ: BTAI) is one of 547 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare BioXcel Therapeutics to related companies based on the strength of its profitability, analyst recommendations, dividends, risk, earnings, institutional ownership and valuation.
This is a breakdown of current ratings and price targets for BioXcel Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioXcel Therapeutics Competitors||4513||12963||27599||992||2.54|
Insider and Institutional Ownership
15.5% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 46.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 64.8% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares BioXcel Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioXcel Therapeutics||N/A||-$19.27 million||-7.72|
|BioXcel Therapeutics Competitors||$2.17 billion||$230.01 million||-3.57|
BioXcel Therapeutics’ peers have higher revenue and earnings than BioXcel Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares BioXcel Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioXcel Therapeutics Competitors||-1,760.46%||-120.17%||-28.09%|
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is based in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.